MEDIA

Bridget Lacey Appointed Chief Business Officer at Nanexa

22 April, 2025
- Regulatory
Download attachment

Nanexa AB is pleased to announce the appointment of Bridget Lacey as Chief Business Officer. With over 25 years of corporate and business development experience across the life sciences sector, Bridget further strengthens Nanexa's leadership team. Bridget's role will initially be on a part-time basis.

David Westberg, CEO of Nanexa, comments, “Nanexa is in a phase where we are placing significant focus on business development. We are therefore pleased to welcome Bridget Lacey. Her extensive experience brings valuable expertise and strategic capabilities to Nanexa.”

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Bridget Lacey Appointed Chief Business Officer at Nanexa